Entinostat (MS-275, SNDX-275): Selective Oral Class I HDAC Inhibitor for Cancer Research

Executive Summary: Entinostat (MS-275, SNDX-275) is a potent, orally bioavailable inhibitor of class I histone deacetylases (HDAC1, HDAC3, and HDAC8), with IC50 values of 0.368 μM for HDAC1 and 0.501 μM for HDAC3, exhibiting strong selectivity for these isoforms (Schwartz 2022). It modulates gene expression through histone acetylation, resulting in anti-proliferative and pro-apoptotic effects in multiple cancer cell lines. Preclinical studies have demonstrated significant tumor burden reduction in animal models, such as retinoblastoma, with corresponding increases in acetyl-histone levels. Entinostat demonstrates solubility in DMSO (≥18.8 mg/mL) and ethanol (≥7.4 mg/mL with sonication), but is insoluble in water (APExBIO). Early-phase clinical trials have established tolerable dosing regimens and confirmed its utility in combination therapies for solid tumors.

Biological Rationale

Histone deacetylases (HDACs) regulate chromatin structure and gene expression by removing acetyl groups from lysine residues on histone tails. Class I HDACs, particularly HDAC1 and HDAC3, are frequently overexpressed in a range of human cancers and are associated with proliferation, survival, and silencing of tumor suppressor genes (Schwartz 2022). Inhibitors targeting these enzymes, such as Entinostat, restore acetylation, leading to reactivation of silenced genes and induction of growth arrest or apoptosis in malignant cells. This epigenetic intervention aligns with the growing interest in modulating the tumor microenvironment and reversing oncogenic transcriptional programs. Entinostat’s selectivity for class I HDACs positions it as a precision tool for dissecting HDAC-driven oncogenic pathways and evaluating epigenetic therapeutic strategies.

Mechanism of Action of Entinostat (MS-275, SNDX-275)

Entinostat acts as a competitive inhibitor of class I HDACs, binding the active site to block deacetylation of histone lysines. This inhibition leads to accumulation of acetylated histones, resulting in relaxed chromatin structure and increased transcriptional activity of genes involved in cell cycle arrest, differentiation, and apoptosis. The observed IC50 values—0.368 μM (HDAC1), 0.501 μM (HDAC3), and 63.4 μM (HDAC8)—demonstrate its strong selectivity for HDAC1 and HDAC3 over HDAC8 (APExBIO). Downstream effects include upregulation of tumor suppressor genes (e.g., p21^WAF1), induction of G1 cell cycle arrest, increased activation of caspase-3/7, and modulation of pro- and anti-apoptotic proteins (Schwartz 2022). In some cancer models, Entinostat also induces reactive oxygen species (ROS) production, contributing to its cytotoxicity.

Evidence & Benchmarks

• Entinostat inhibits proliferation in breast, colon, lung, ovary, pancreas, prostate, and leukemia cell lines, with growth inhibition and apoptosis observed at sub-micromolar concentrations (Schwartz 2022).
• Selective inhibition: IC50 for HDAC1 is 0.368 μM, for HDAC3 is 0.501 μM, and for HDAC8 is 63.4 μM, supporting high specificity for class I HDACs (APExBIO).
• In retinoblastoma animal models, systemic administration of Entinostat significantly reduced tumor burden and increased acetyl-histone levels in retinal tissue (Schwartz 2022).
• Phase I clinical trials combining Entinostat with 13-cis retinoic acid established a recommended phase II dose and documented a tolerable safety profile in advanced solid tumor patients (Schwartz 2022).
• Stock solutions are stable in DMSO (≥18.8 mg/mL) and ethanol (≥7.4 mg/mL with ultrasonication), but degrade if not stored below -20°C (APExBIO).
• In vitro evaluation protocols distinguish between proliferative arrest and cell death, underscoring the importance of fractional viability assays in HDAC inhibitor studies (Schwartz 2022).

This article extends the practical focus of "Entinostat (MS-275, SNDX-275): Precision HDAC1/3 Inhibition" by providing granular, citation-backed benchmarks and solubility parameters for rigorous workflow planning. For a deeper mechanistic and translational discussion, see "Entinostat (MS-275, SNDX-275): Mechanistic Precision and Translational Outlook", which this article updates with the latest evidence and experimental nuances.

Applications, Limits & Misconceptions

Entinostat is widely used in cancer research for: (i) dissecting HDAC-mediated transcriptional regulation, (ii) screening anti-proliferative and pro-apoptotic effects in tumor cell lines, (iii) preclinical in vivo models of solid tumors and hematologic malignancies, and (iv) clinical trial protocols for advanced solid tumors. It supports investigation of tumor suppressor gene reactivation, cell cycle dynamics, and drug synergy with retinoids or chemotherapeutics. Additionally, Entinostat serves as a model compound for benchmarking new HDAC inhibitors and validating epigenetic screening platforms.

Common Pitfalls or Misconceptions

• Water Insolubility: Entinostat is not soluble in water; attempts at aqueous dissolution result in precipitation or loss of activity.
• Non-selectivity at High Concentrations: At concentrations far above the IC50 for HDAC1/3, off-target effects may occur, potentially confounding results.
• No Direct Cytotoxicity in All Cell Types: Some non-malignant cells may show limited sensitivity, reflecting context-dependent epigenetic regulation.
• Storage Sensitivity: Stock solutions degrade rapidly at temperatures above -20°C or after repeated freeze-thaw cycles.
• Not a Pan-HDAC Inhibitor: Entinostat does not robustly inhibit class II HDACs or HDAC8 at pharmacologically relevant doses.

Workflow Integration & Parameters

For experimental use, dissolve Entinostat (MS-275, SNDX-275) in DMSO to prepare stock solutions up to 18.8 mg/mL, or in ethanol up to 7.4 mg/mL with sonication (APExBIO). Store aliquots below -20°C and avoid repeated freeze-thaw cycles. In vitro assays typically apply Entinostat at 0.1–5 μM for 24–72 hours, depending on cell type and endpoint (viability, apoptosis, or gene expression). For in vivo research, dosing regimens should follow established protocols, often combining Entinostat with other agents to assess synergy or resistance mechanisms. Fractional viability (cell death) and relative viability (growth inhibition) should be measured independently (Schwartz 2022).

The A8171 kit from APExBIO offers validated quality for reproducible results. For practical troubleshooting and workflow optimization, see "Optimizing Cancer Cell Assays with Entinostat (MS-275, SNDX-275)", which this article extends by detailing solubility and storage parameters.

Conclusion & Outlook

Entinostat (MS-275, SNDX-275) is a benchmark oral class I HDAC inhibitor, enabling precise epigenetic modulation in oncology research. Its selective inhibition of HDAC1 and HDAC3, robust anti-proliferative effects, and favorable solubility profile support its widespread adoption in translational and preclinical studies. The product, available from APExBIO, is instrumental in advancing mechanistic understanding and therapeutic development targeting HDAC-mediated pathways. Ongoing clinical trials and innovative combinatorial strategies underscore Entinostat's potential to shape the future of cancer epigenetics.